Precigen, Inc. (PGEN) Dividend History

Company News

• Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment

  Precigen has submitted a biologics license application to the FDA for PRGN-2012, a potential first treatment for recurrent respiratory papillomatosis. The submission is a significant step forward, as PRGN-2012 has received Breakthrough Therapy and Orphan Drug Designations from the FDA.

  Benzinga
• Wall Street Breakfast: The Week Ahead

  Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.

  Seeking Alpha

  Featured Companies: A ALDX BBWI BF.A COUR CPB CRWD CSCO DAC DLO DLR DLTR DOCU EQIX ETR FIVE GILD GSL GTLB HOLO HOOD HPE INVH IOT K KHC LEG LULU NVDA O PG PM PSA PVH SAFE SAIC SBUX SJM SKT SLG SNOW SVRA SYY ULS VICI WMT
• Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates

  Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: MYNZ
• 10 Top Penny Stocks To Buy According To Insiders In August

  Penny stocks to buy according to these insiders this month. The post 10 Top Penny Stocks To Buy According To Insiders In August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: BVS COMM GCI NOTE REAL RXT
• 2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years

  Biotechs are capable of making huge gains in short periods, and they often do.

  The Motley Fool